Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIOP) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Fortress Biotech (FBIOP) over the last 9 years, with Q3 2025 value amounting to $135000.0.

  • Fortress Biotech's Other Accumulated Expenses fell 8699.42% to $135000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $135000.0, marking a year-over-year decrease of 8699.42%. This contributed to the annual value of $1.5 million for FY2024, which is 82269.94% up from last year.
  • Latest data reveals that Fortress Biotech reported Other Accumulated Expenses of $135000.0 as of Q3 2025, which was down 8699.42% from $2.1 million recorded in Q2 2025.
  • In the past 5 years, Fortress Biotech's Other Accumulated Expenses ranged from a high of $2.1 million in Q1 2025 and a low of $135000.0 during Q3 2025
  • Its 4-year average for Other Accumulated Expenses is $934833.3, with a median of $1.0 million in 2022.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first crashed by 8797.05% in 2024, then skyrocketed by 121349.69% in 2025.
  • Quarter analysis of 4 years shows Fortress Biotech's Other Accumulated Expenses stood at $996000.0 in 2022, then tumbled by 83.63% to $163000.0 in 2023, then surged by 822.7% to $1.5 million in 2024, then tumbled by 91.02% to $135000.0 in 2025.
  • Its last three reported values are $135000.0 in Q3 2025, $2.1 million for Q2 2025, and $2.1 million during Q1 2025.